• Three new manufacturing lines were successfully launched in under ten months, with an  additional eight new lines planned to launch in Q3 2022.  
• Sustain and secure the supply chain for customers in China and the broader region.  • With the use of Fortem™ film, Cytiva helps customers speed up their clinical manufacturing  and product launches; improve manufacturing efficiency; and increase cost saving. 

The planned expansion will consist of an additional eight new manufacturing lines, two of which  are expected to launch by the end of 2021; with the other six lines scheduled in Q3 2022. It adds  1300 square meters to the manufacturing area of the ISO Class 7 cleanroom and also includes a  1200 square meters warehouse to further save lead time and increase flexibility for customers.  

These expansions are part of the recently-announced USD1.5 billion-dollar investment by Cytiva  and Pall Corporation.  

In addition to the increased capacity, Cytiva also brings new products, 100L to 1,000L Xcellerex mixer bags, to the expanded facility’s manufacturing portfolio. The new products will  incorporate Fortem technology - Cytiva’s materially advanced, single-use characterized film, and  its local manufacture enhances our ability to provide business continuity for our customers.  

Francis Van Parys, Vice President, Asia-Pacific, Cytiva, says: “With the increases in global  demand, customers require more flexibility and adaptability, resulting in the growing trend of  in-region for-region manufacturing. Our collaboration with Wego has proven successful for our  customers in China, and this increased capacity will help the region improve manufacturing  resilience with cost efficiencies and decreased lead times, while delivering an equivalent, high quality product to our customers in the broader region.” 

According to the BioPlan Annual Biomanufacturing report1, the adoption of single-use  technology is expected to increase rapidly in clinical production and in manufacturing. More  than 85% of current pre-commercial and clinical manufacturing lines/facilities are single-use.